Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 in Healthy Japanese Infants
NCT04384107Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Jul 2020; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04384107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384107.